CD44 and neoplasm: In the production of in vivo passages, we found that CD133+CD44+ cells did not lose their tumorigenic potential but instead had enhanced aggressiveness, as indicated by faster tumor growth and an increasing number of CD133+CD44+ cells in newly generated tumors (Figure 3F,G).